Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AugMMent in newly diagnosed transplant-eligible multiple myeloma
2025-523990-40-00Phase 3Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of teclistamab, daratumumab, lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Heidelberg University Hospital. Primary endpoint: Cumulative MRD negativity by NGS before maintenance therapy. Planned start Jul 2026; status: authorised.
02
Drugs
teclistamabdaratumumablenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-523990-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523990-40-00.